Divarasib has advanced to Phase III clinical trials for non-small cell lung cancer (NSCLC) and is evaluated in multiple Phase I/II trials, additionally including patients with metastatic colorectal cancer (CRC) and other advanced or metastatic solid tumors carrying a KRAS(G12C) mutation. Here, KRAS is linked to non-small cell lung carcinoma.